Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;20(4):483-495.
doi: 10.22074/cellj.2019.5591. Epub 2018 Dec 12.

Systemic Infusion of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Peritoneal Dialysis Patients: Feasibility and Safety

Sudabeh Alatab #  1 , Soroosh Shekarchian #  2 , Iraj Najafi  3 , Reza Moghadasali  2   4 , Naser Ahmadbeigi  5 , Mohammad Reza Pourmand  6 , Tina Bolurieh  2 , Neda Jaroughi  2 , Gholamreza Pourmand  7 , Nasser Aghdami  8
Affiliations

Systemic Infusion of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Peritoneal Dialysis Patients: Feasibility and Safety

Sudabeh Alatab et al. Cell J. 2019 Jan.

Abstract

Objective: Using mesenchymal stem cells (MSCs) is regarded as a new therapeutic approach for improving fibrotic diseases. the aim of this study to evaluate the feasibility and safety of systemic infusion of autologous adipose tissue-derived MSCs (AD-MSCs) in peritoneal dialysis (PD) patients with expected peritoneal fibrosis.

Materials and methods: This study was a prospective, open-label, non-randomized, placebo-free, phase I clinical trial. Case group consisted of nine eligible renal failure patients with more than two years of history of being on PD. Autologous AD-MSCs were obtained through lipoaspiration and expanded under good manufacturing practice conditions. Patients received 1.2 ± 0.1×106 cell/kg of AD-MSCs via cubital vein and then were followed for six months at time points of baseline, and then 3 weeks, 6 weeks, 12 weeks, 16 weeks and 24 weeks after infusion. Clinical, biochemical and peritoneal equilibration test (PET) were performed to assess the safety and probable change in peritoneal solute transport parameters.

Results: No serious adverse events and no catheter-related complications were found in the participants. 14 minor reported adverse events were self-limited or subsided after supportive treatment. One patient developed an episode of peritonitis and another patient experienced exit site infection, which did not appear to be related to the procedure. A significant decrease in the rate of solute transport across peritoneal membrane was detected by PET (D/P cr=0.77 vs. 0.73, P=0.02).

Conclusion: This study, for the first time, showed the feasibility and safety of AD-MSCs in PD patients and the potentials for positive changes in solute transport. Further studies with larger samples, longer follow-up, and randomized blind control groups to elucidate the most effective route, frequency and dose of MSCs administration, are necessary (Registration Number: IRCT2015052415841N2).

Keywords: End Stage Renal Disease; Mesenchymal Stem Cell; Peritoneal Dialysis; Peritoneal Fibrosis.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest in this study.

References

    1. Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012;23(3):533–544. - PMC - PubMed
    1. Najafi I, Alatab S, Atabak S, Majelan NN, Sanadgol H, Makhdoomi K, et al. Seventeen years’ experience of peritoneal dialysis in Iran: First official report of the Iranian peritoneal dialysis registry. Perit Dial Int. 2014;34(6):636–642. - PMC - PubMed
    1. Termorshuizen F, Korevaar JC, Dekker FW, Van Manen JG, Boeschoten EW, Krediet RT, et al. Netherlands cooperative study on the adequacy of dialysis study group.Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of the netherlands cooperative study on the adequacy of dialysis 2. J Am Soc Nephrol. 2003;14(11):2851–2860. - PubMed
    1. Zhou Q, Bajo MA, Del Peso G, Yu X, Selgas R. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int. 2016;90(3):515–524. - PubMed
    1. Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34(6):747–754. - PMC - PubMed

LinkOut - more resources